Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: Validation with surgical specimens

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 6, 2013, Pages 824-831

  Bundschuh, Ralph A ^a,b   Wendl, Christina M ^a   Weirich, Gregor ^c   Eiber, Mathias ^a   Souvatzoglou, Michael ^a   Treiber, Uwe ^a   Kübler, Hubert ^a   Maurer, Tobias ^a   Gschwend, Jürgen E ^a   Geinitz, Hans ^a   Grosu, Anca L ^d   Ziegler, Sibylle I ^a   Krause, Bernd Joachim ^a,e  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

Author keywords

Choline; PET CT; Prostate; Target volume definition

Indexed keywords

CHOLINE C 11; PROSTATE SPECIFIC ANTIGEN; CARBON; CHOLINE; RADIOPHARMACEUTICAL AGENT;

ALGORITHM; ARTICLE; CANCER LOCALIZATION; CANCER SIZE; CHOLINE UPTAKE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EX VIVO STUDY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; MALE; PET-CT SCANNER; PROSPECTIVE STUDY; PROSTATE CARCINOMA; PROSTATECTOMY; CARCINOMA; IMAGE PROCESSING; MULTIMODAL IMAGING; PATHOLOGY; PROSTATE TUMOR; REPRODUCIBILITY; TUMOR VOLUME; PROSTATIC NEOPLASMS;

ALGORITHMS; CARBON RADIOISOTOPES; CARCINOMA; CHOLINE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MULTIMODAL IMAGING; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; TUMOR BURDEN;

EID: 84883281085     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2345-7     Document Type: Article

References (38)

1. Damber JE, Aus G. Prostate cancer. Lancet. 2008;371:1710-21.
2. Pasquier D, Ballereau C. Adjuvant and salvage radiotherapy after prostatectomy for prostate cancer: a literature review. Int J Radiat Oncol Biol Phys. 2008;72:972-9.
3. Zelefsky MJ, Pei X, Chou JF, Schechter M, Kollmeier M, Cox B, et al. Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol. 2011;60:1133-9.
4. Ashamalla H, Rafla S, Parikh K, Mokhtar B, Goswami G, Kambam S, et al. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer. Int J Radiat Oncol Biol Phys. 2005;63:1016-23.
5. van Baardwijk A, Baumert BG, Bosmans G, van Kroonenburgh M, Stroobants S, Gregoire V, et al. The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat Rev. 2006;32:245-60.
6. Astner ST, Theodorou M, Dobrei-Ciuchendea M, Auer F, Kopp C, Molls M, et al. Tumor shrinkage assessed by volumetric MRI in the long-term follow-up after stereotactic radiotherapy of meningiomas. Strahlenther Onkol. 2010;186:423-9.
7. Bundschuh RA, Andratschke N, Dinges J, Duma MN, Astner ST, Brügel M, et al. Respiratory gated [(18)F]FDG PET/CT for target volume delineation in stereotactic radiation treatment of liver metastases. Strahlenther Onkol. 2012;188:592-8.
8. Astner ST, Dobrei-Ciuchendea M, Essler M, Bundschuh RA, Sai H, Schwaiger M, et al. Effect of 11C-methionine-positron emission tomography on gross tumor volume delineation in stereotactic radiotherapy of skull base meningiomas. Int J Radiat Oncol Biol Phys. 2008;72:1161-7.
9. Pinkawa M, Piroth MD, Holy R, Klotz J, Djukic V, Corral NE, et al. Dose-escalation using intensity-modulated radiotherapy for prostate cancer - evaluation of quality of life with and without (18)F-choline PET-CT detected simultaneous integrated boost. Radiat Oncol. 2012;7:14.
10. Kotzerke J, Prang J, Neumaier B, Volkmer B, Guhlmann A, Kleinschmidt K, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med. 2000;27:1415-9.
11. Schmid DT, John H, Zweifel R, Cservenyak T, Westera G, Goerres GW, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology. 2005;235:623-8.
12. Krause BJ, Souvatzoglou M, Treiber U. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates. Urol Oncol. 2011. doi:10.1016/j.urolonc.2010.08.008
13. Piert M, Park H, Khan A, Siddiqui J, Hussain H, Chenevert T, et al. Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques. J Nucl Med. 2009;50:1585-93.
14. Yamaguchi T, Lee J, Uemura H, Sasaki T, Takahashi N, Oka T, et al. Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging. 2005;32:742-8.
15. Reske SN, Blumstein NM, Neumaier B, Gottfried HW, Finsterbusch F, Kocot D, et al. Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med. 2006;47:1249-54.
16. Souvatzoglou M,Weirich G, Schwarzenboeck S,Maurer T, Schuster T, Bundschuh RA, et al. The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res. 2011;17:3751-9.
17. Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G, et al. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med. 2005;46:1642-9.
18. Astner ST, Bundschuh RA, Beer AJ, Ziegler SI, Krause BJ, Schwaiger M, et al. Assessment of tumor volumes in skull base glomus tumors using Gluc-Lys[(18)F]-TOCA positron emission tomography. Int J Radiat Oncol Biol Phys. 2009;73:1135-40.
19. Daisne JF, Duprez T,Weynand B, Lonneux M, Hamoir M, Reychler H, et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT,MR imaging, and FDG PET and validation with surgical specimen. Radiology. 2004;233:93-100.
20. Martinez MJ, Bercier Y, Schwaiger M, Ziegler SI. PET/CT Biograph Sensation 16: performance improvement using faster electronics. Nuklearmedizin. 2006;3:126-33.
21. Schned AR, Wheeler KJ, Hodorowski CA, Heaney JA, Ernstoff MS, Amdur RJ, et al. Tissue-shrinkage correction factor in the calculation of prostate cancer volume. Am J Surg Pathol. 1996;20:1501-6.
22. Kwee SA, Coel MN, Lim J, Ko JP. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol. 2005;173:252-5.
23. Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F, et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology. 2010;254:925-33.
24. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Visualization of prostate cancer with 11C-choline positron emission tomography. Eur Urol. 2002;42:18-23.
25. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. 11Ccholine positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol. 2003;44:32-8. discussion 38-39.
26. Giovacchini G, Picchio M, Coradeschi E, Scattoni V, Bettinardi V, Cozzarini C, et al. [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging. 2008;35:1065-73.
27. Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A, et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:253-63.
28. 18F-fluorocholine PET. J Nucl Med. 2006;47:262-9.
29. Martorana G, Schiavina R, Corti B, Farsad M, Salizzoni E, Brunocilla E, et al. 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol. 2006;176:954-60. discussion 960.
30. Scher B, Seitz M, Albinger W, Tiling R, Scherr M, Becker HC, et al. Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging. 2007;34:45-53.
31. Schiavina R, Scattoni V, Castellucci P, Picchio M, Corti B, Briganti A, et al. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediaterisk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol. 2008;54:392-401.
32. Steuber T, Schlomm T, Heinzer H, Zacharias M, Ahyai S, Chun KF, et al. [F(18)]-fluoroethylcholine combined in-line PET-CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: Preliminary results from a prospective histology-based study. Eur J Cancer. 2010;46:449-55.
33. Sutinen E, Nurmi M, Roivainen A, Varpula M, Tolvanen T, Lehikoinen P, et al. Kinetics of [(11)C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging. 2004;31:317-24.
34. 18F-fluorodeoxyglucose PET and MR imaging. J Magn Reson Imaging. 2010;31:1151-6.
35. Yoshida S, Nakagomi K, Goto S, Futatsubashi M, Torizuka T. 11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging. Urol Int. 2005;74:214-20.
36. Li X, Liu Q, Wang M, Jin X, Liu Q, Yao S, et al. C-11 choline PET/CT imaging for differentiating malignant from benign prostate lesions. Clin Nucl Med. 2008;33:671-6.
37. Bradley JD, Perez CA, Dehdashti F, Siegel BA. Implementing biologic target volumes in radiation treatment planning for nonsmall- cell lung cancer. J Nucl Med. 2004;45:96S-101.
38. Ciernik IF, Huser M, Burger C, Davis JB, Szekely G. Automated functional image-guided radiation treatment planning for rectal cancer. Int J Radiat Oncol Biol Phys. 2005;62:893-900.